© February 2024 | IJIRT | Volume 10 Issue 9 | ISSN: 2349-6002

Microbes and Medicine: A Review of Therapeutic Applications

Kartiki Rangnath Desai [1*]
[1] *K.J. Somaiya College of Arts, Commerce and Science, Kopargaon, Maharashtra, India.*

***Abstract*— Microbes play a pivotal role in modern medicine, contributing to therapeutic advancements in diverse ways. This comprehensive review explores the myriad applications of microbes in medicine, ranging from their roles as sources of therapeutic agents to their utilization in various treatment modalities. The review begins with an overview of the microbial sources of therapeutic agents, encompassing natural products such as antibiotics, antifungals, and antivirals, as well as engineered microbes engineered to produce biologics and serve as gene therapy vectors. Furthermore, microbial therapy approaches, including probiotics, phage therapy, and microbial immunotherapy, are examined in detail, elucidating their mechanisms of action and clinical applications.**

In addition, the review delves into microbial engineering strategies, such as synthetic biology approaches and the utilization of CRISPR-Cas systems, for the development of tailored microbial therapies. Clinical considerations and challenges, such as safety concerns and regulatory frameworks, are also explored, providing insights into the current landscape of microbial therapy research. Finally, future directions in microbial therapy research are discussed, highlighting emerging trends and the potential impact on future medical practices. Through this review, the significant contributions of microbes to the field of medicine are underscored, emphasizing the promising prospects of microbial-based therapies in addressing various health challenges.

***Index Terms*— Clinical considerations, CRISPR-Cas, Future directions, Medicine, Microbes, Phage therapy, Probiotics, Synthetic biology, Therapeutic applications**

I. INTRODUCTION

In the realm of medicine, the intricate dance between humanity and microorganisms continues to unveil awe-inspiring discoveries, fundamentally reshaping our understanding of health and disease. The symbiotic relationship between humans and microbes has long been recognized, but recent research has illuminated the profound implications of microbial communities for human well-being. This introduction sets the stage for exploring the dynamic landscape of microbiology and its transformative impact on modern medicine, drawing from current research findings to navigate the intricate web of microbial marvels.

Advancements in high-throughput sequencing technologies have revolutionized our ability to explore the complex microbial ecosystems that inhabit the human body. The Human Microbiome Project (HMP) and other initiatives have provided unprecedented insights into the diversity and dynamics of microbial communities residing on and within us. From the gut to the skin, from the oral cavity to the reproductive tract, microbes orchestrate a symphony of interactions that influence physiological processes, immune function, and susceptibility to diseases.

Moreover, research has elucidated the intricate crosstalk between the microbiome and the host immune system, revealing a delicate balance that underpins health and disease. Dysbiosis, or microbial imbalance, has emerged as a hallmark of numerous medical conditions, including inflammatory bowel diseases, metabolic disorders, and neurodegenerative diseases. Understanding the mechanisms driving these dysbiotic states holds immense therapeutic potential, paving the way for microbiome-targeted interventions to restore microbial equilibrium and promote health.

The era of precision medicine has ushered in a paradigm shift in healthcare, wherein treatment strategies are tailored to individual characteristics, including genetic makeup, lifestyle factors, and now, microbial profiles.[1] The concept of "microbiome medicine" is rapidly gaining traction, fueled by a growing body of evidence linking microbial composition to disease susceptibility, treatment response, and prognosis. Integrating microbiome data into clinical decision-making holds promise for optimizing patient outcomes and ushering in a new era of personalized healthcare.[2]

Beyond the confines of the human body, microbes continue to wield influence on global health through their roles in infectious diseases, antimicrobial resistance, and environmental microbiology. Emerging infectious agents, such as novel viruses and drug-resistant bacteria, pose formidable challenges to public health preparedness and highlight the urgent need for vigilant surveillance and rapid response capabilities. Moreover, the interconnectedness of microbial communities within ecosystems underscores the importance of ecological approaches to understanding and mitigating infectious disease outbreaks.[3]

In parallel, the field of microbial biotechnology is undergoing a renaissance, driven by innovations in genetic engineering, synthetic biology, and bioinformatics. Microbes serve as versatile workhorses for producing a wide array of bioactive compounds, including pharmaceuticals, enzymes, and biofuels. Engineered microbes with enhanced capabilities are poised to revolutionize industrial processes, agriculture, and environmental remediation, offering sustainable solutions to pressing global challenges. [4.5]

Furthermore, the advent of CRISPR-Cas gene editing technology has unlocked new frontiers in microbiology, enabling precise manipulation of microbial genomes for therapeutic and biotechnological applications.[6] CRISPR-based tools hold promises for combating antimicrobial resistance, engineering probiotic organisms, and developing novel antimicrobial agents, underscoring their transformative potential in addressing longstanding challenges in microbiology and medicine.[7] The convergence of cutting-edge technologies, interdisciplinary collaborations, and a deepening understanding of microbial biology is reshaping the landscape of modern medicine.[8] From the intricate interplay between the human microbiome and host physiology to the potential of microbial biotechnology and CRISPR-based therapeutics, the possibilities are boundless. As we embark on this journey of exploration and innovation, the microbial world continues to reveal its marvels, offering tantalizing glimpses into a future where microbes are harnessed as allies in the pursuit of health and well-being. [9,10]

II. MICROBIAL THERAPY APPROACHES: HARNESSING THE POWER OF MICROBES FOR HEALTH

Microbial therapy approaches represent a burgeoning field at the intersection of microbiology and medicine, offering novel strategies for disease prevention, treatment, and management. Recent research has illuminated the diverse mechanisms by which microbes can be harnessed to promote human health, ranging from probiotics and phage therapy to microbial immunotherapy. [11,12] This section explores key findings from current research on microbial therapy approaches, shedding light on their mechanisms of action, clinical applications, and therapeutic potential.[13]

Probiotics, defined as live microorganisms that confer health benefits when administered in adequate amounts, have garnered considerable attention for their potential roles in modulating the gut microbiota and supporting digestive health. Recent studies have provided insights into the mechanisms underlying the beneficial effects of probiotics, including their ability to enhance gut barrier function, modulate immune responses, and regulate microbial composition. Clinical trials have demonstrated the efficacy of probiotic supplementation in various gastrointestinal disorders, such as irritable bowel syndrome, inflammatory bowel disease, and antibiotic-associated diarrhea, highlighting their therapeutic potential in the management of gut-related ailments. [14,15]

Phage therapy, the use of bacteriophages to selectively target and eliminate pathogenic bacteria, has emerged as a promising alternative to conventional antibiotics in the face of rising antimicrobial resistance.[16] Recent research has focused on the isolation and characterization of phages with lytic activity against multidrug-resistant pathogens, including Methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, and Escherichia coli. Clinical trials have

Table 1. Key Applications of Microbes in Various Medical Fields [17]

Application Category	Specific Application	Microbes Used	Mechanism of Action	Examples
Therapeutics & Diagnostics	Antibiotics & Antifungals	Bacteria (e.g., Penicillium, Streptomyces)	Produce natural compounds that kill or inhibit pathogenic microbes	Penicillin, Tetracycline, Fluconazole
	Vaccines	Bacteria, Viruses (attenuated or inactivated)	Trigger immune response against specific pathogens	Live attenuated vaccines (e.g., MMR), Inactivated vaccines (e.g., Polio)
	Diagnostics	Bacteria, Viruses, Fungi	Utilize metabolic activity or specific biomarkers for pathogen detection	Rapid strep tests, Blood agar plates, Enzyme-linked immunosorbent assay (ELISA)
Microbiome Modulation	Probiotics & Prebiotics	Live, beneficial bacteria & non-digestible fibers	Restore balance and function of gut microbiome	Yogurt with Bifidobacterium and Lactobacillus, Inulin supplements
	Fecal Microbiota Transplant (FMT)	Gut microbiota from healthy donor	Replaces gut microbiome of recipient with healthier one	Treats antibiotic-resistant infections, Inflammatory bowel disease (IBD)
	Dietary Interventions	None (Focuses on dietary impact on gut microbiome)	Specific dietary patterns (e.g., Mediterranean diet)	Promote growth of beneficial microbes and inhibit harmful ones
Emerging Applications	Personalized Medicine	Engineered microbes	Tailored to individual's genetic or microbial profile	Microbiome-based cancer therapies, Targeted drug delivery using engineered microbes
	Regenerative Medicine	Various microbes	Promote tissue repair and regeneration	Research ongoing in areas like wound healing, bone regeneration
	Phage Therapy	Bacteriophages (viruses that infect bacteria)	Specifically target and kill pathogenic bacteria	Potential alternative to antibiotics, especially for resistant strains

demonstrated the safety and efficacy of phage therapy in treating various bacterial infections, including chronic wounds, urinary tract infections, and respiratory tract infections, underscoring its potential as a personalized and precision-based approach to infection control.[18]

Microbial immunotherapy harnesses the immunomodulatory properties of microorganisms to modulate immune responses and treat immune-related disorders. Recent research has elucidated the mechanisms by which commensal bacteria, such as certain strains of Lactobacillus and Bifidobacterium, interact with the host immune system to promote immune tolerance and suppress inflammation.[19] Clinical trials have explored the use of microbial immunotherapy in the management of autoimmune diseases, allergic disorders, and inflammatory conditions, with promising results suggesting the potential for microbiome-based interventions to restore immune homeostasis and alleviate disease symptoms.[20]

Engineered microbes are being developed as therapeutic agents for targeted delivery of therapeutic payloads, such as drugs, enzymes, and biologics, to specific tissues or disease sites. Recent advances in synthetic biology and genetic engineering have enabled the design and construction of genetically modified microorganisms with enhanced therapeutic properties, including tumor-targeting capabilities, drug synthesis capabilities, and controlled release mechanisms. Preclinical studies have demonstrated the feasibility and efficacy of engineered microbial therapeutics in various disease models, paving the way for clinical translation and therapeutic applications in humans.[21] Microbial therapy approaches offer innovative and versatile strategies for promoting human health and combating disease. From probiotics and phage therapy to microbial immunotherapy and engineered microbes, recent research findings underscore the diverse mechanisms by which microorganisms can be harnessed to modulate host physiology, regulate immune responses, and target disease processes. As our understanding of the complex interplay between microbes and the host continues to deepen, the therapeutic potential of microbial therapy approaches is poised to revolutionize clinical practice and usher in a new era of personalized medicine.[22]

III. MICROBIAL ENGINEERING FOR THERAPEUTIC PURPOSES: REVOLUTIONIZING TREATMENT MODALITIES

Microbial engineering represents a cutting-edge approach to therapeutic development, leveraging the power of genetic manipulation and synthetic biology to engineer microorganisms with enhanced therapeutic properties. Recent research in this field has yielded remarkable insights and innovations, offering new avenues for the treatment of various diseases and medical conditions. This section explores key findings from current research on microbial engineering for therapeutic purposes, highlighting advancements in synthetic biology, CRISPR-Cas systems, and the development of engineered microbial therapeutics.

Synthetic biology approaches enable the rational design and construction of microbial systems with customized functions and properties, revolutionizing our ability to engineer microorganisms for therapeutic applications.[23] Recent research has focused on the design and optimization of synthetic gene circuits, metabolic pathways, and regulatory networks to confer desired traits, such as drug synthesis capabilities, targeted delivery mechanisms, and environmental sensing capabilities. Engineered microbes are being developed as platforms to produce biologics, biosensors, and biofuels, offering scalable and sustainable solutions to pressing healthcare and environmental challenges.[24]

One area of intense research interest is the development of engineered microbial therapeutics for targeted drug delivery and controlled release. Recent advances in genetic engineering have enabled the design of microbial vectors capable of delivering therapeutic payloads, such as drugs, enzymes, and nucleic acids, to specific tissues or disease sites. Engineered bacteria, yeast, and viruses are being explored as delivery vehicles for cancer therapy, gene therapy, and regenerative medicine, offering precise and localized delivery of therapeutic agents with reduced systemic toxicity.[25]

CRISPR-Cas systems have emerged as powerful tools for genome editing and genetic manipulation, offering unprecedented precision and efficiency in modifying microbial genomes for therapeutic purposes. Recent research has demonstrated the potential of CRISPR-based approaches for engineering microbial therapeutics with enhanced functionalities, such as improved targeting specificity, reduced off-target effects, and enhanced therapeutic efficacy. CRISPR-engineered bacteria, phages, and yeast are being developed as next-generation antimicrobials, cancer therapeutics, and immunomodulatory agents, heralding a new era of precision medicine and personalized therapy.[26]

Microbes are being engineered to modulate host-microbiome interactions and restore microbial homeostasis in various disease states. Recent research has focused on the development of probiotic bacteria engineered to express therapeutic proteins, metabolites, or signaling molecules that promote gut health, modulate immune responses, and mitigate inflammatory disorders. Engineered probiotics are being investigated as potential treatments for gastrointestinal diseases, metabolic disorders, and autoimmune conditions, offering targeted and personalized interventions that harness the therapeutic potential of the gut microbiota. Microbial engineering holds immense promise for revolutionizing therapeutic modalities and addressing unmet medical needs.[27] From synthetic biology approaches to CRISPR-based genome editing, recent research findings underscore the transformative potential of microbial engineering for developing novel therapeutics with enhanced efficacy, specificity, and safety profiles. As our understanding of microbial biology and genetic engineering continues to advance, the therapeutic landscape is poised to be reshaped by the emergence of engineered microbial therapeutics tailored to individual patient's needs, ushering in a new era of precision medicine and personalized therapy.[28]

IV. CLINICAL CONSIDERATIONS AND CHALLENGES IN MICROBIAL THERAPY

If you are using Word, use either the Microsoft Equation E While microbial therapy holds great promise for revolutionizing medicine, its clinical implementation presents various considerations and challenges that must be addressed to ensure safety, efficacy, and regulatory compliance. This section explores key clinical considerations and challenges in microbial therapy, drawing from current research findings and clinical experiences to provide insights into the complexities of translating microbial-based therapies from bench to bedside.[29]

One of the primary considerations in microbial therapy is safety, as the introduction of live microorganisms into the human body carries inherent risks of adverse effects and unintended consequences. Recent research has focused on the safety profiles of microbial therapeutics, assessing their potential for colonization, dissemination, and host immune responses. Preclinical studies and early-phase clinical trials play a crucial role in evaluating the safety and tolerability of microbial-based therapies, providing valuable data on dosing regimens, route of administration, and patient selection criteria.[30]

Moreover, the risk of microbial resistance presents a significant challenge in the clinical use of antimicrobial agents, including bacteriophages and engineered microbes. Recent research has highlighted the importance of surveillance and monitoring programs to track the emergence and spread of antimicrobial resistance in microbial populations, informing treatment strategies and guiding the development of novel therapeutics. Combination therapy, phage cocktails, and phage-antibiotic synergy are being explored as potential strategies to mitigate the risk of resistance and enhance the efficacy of antimicrobial treatments.[31]

Another clinical consideration in microbial therapy is regulatory oversight and approval processes, which ensure the safety, efficacy, and quality of microbial-based therapeutics before they can be brought to market. Recent regulatory developments have focused on establishing clear guidelines and frameworks for the evaluation and approval of microbial therapeutics, balancing the need for innovation with rigorous safety and efficacy standards. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), play a pivotal role in reviewing and approving microbial-based therapies, providing guidance to developers, and facilitating the translation of promising candidates into clinical practice.[32]

The complexity of host-microbiome interactions presents challenges in predicting and optimizing therapeutic outcomes in microbial therapy. Recent research has highlighted the importance of patient-specific factors, such as age, genetics, diet, and comorbidities, in shaping the composition and function of the microbiome and influencing treatment responses. Personalized approaches, such as microbiome profiling, metagenomic analysis, and machine learning algorithms, are being explored to tailor microbial-based therapies to individual patients' microbiome signatures, optimizing efficacy and minimizing adverse effects. While microbial therapy holds tremendous potential for transforming the landscape of medicine, its clinical implementation requires careful consideration of safety, efficacy, regulatory, and personalized medicine. Recent research findings and clinical experiences provide valuable insights into the complexities and challenges of translating microbial-based therapies from bench to bedside, guiding the development and optimization of novel therapeutics that harness the therapeutic potential of the microbiome to improve human health. Continued research and collaboration between academia, industry, and regulatory agencies are essential to overcome these challenges and unlock the full promise of microbial therapy in clinical practice.[33]

V. FUTURE DIRECTIONS AND CONCLUSION

The future of microbial therapy is brimming with exciting possibilities, propelled by rapid advancements in microbiology, biotechnology, and clinical research. This section explores key future directions in microbial therapy and concludes with reflections on the transformative potential of microbial-based interventions in shaping the future of healthcare. One promising avenue for future research in microbial therapy is the development of personalized and precision-based approaches that leverage the unique characteristics of individual patients' microbiomes to tailor therapeutic interventions. Advances in metagenomics, computational modelling, and machine learning are poised to revolutionize our ability to predict, monitor, and modulate microbial communities, enabling the design of bespoke therapies that optimize efficacy and minimize adverse effects.[34]

Moreover, the integration of microbial therapy with other treatment modalities, such as immunotherapy, chemotherapy, and precision oncology, holds promise for synergistic therapeutic outcomes and enhanced patient outcomes. Combination therapies that target multiple pathways and mechanisms of disease are being explored to overcome treatment resistance, improve response rates, and prolong survival in patients with cancer, infectious diseases, and other medical conditions. The development of novel delivery platforms and formulations for microbial-based therapeutics represents a fertile area for future innovation. Advances in nanotechnology, biomaterials, and targeted drug delivery systems are enabling precise and controlled release of therapeutic agents, enhancing their bioavailability, stability, and tissue-specific targeting capabilities. Engineered microbial vectors, synthetic microbial consortia, and microencapsulation technologies offer versatile platforms for delivering therapeutic payloads to specific tissues or disease sites, maximizing therapeutic efficacy, and minimizing systemic toxicity.

In conclusion, microbial therapy represents a paradigm-shifting approach to healthcare, offering novel strategies for disease prevention, treatment, and management that harness the therapeutic potential of the microbiome. As we look to the future, the convergence of cutting-edge technologies, interdisciplinary collaborations, and a deepening understanding of microbial biology is poised to unlock new frontiers in microbial therapy, reshaping the landscape of medicine and improving outcomes for patients worldwide. By embracing innovation, collaboration, and a patient-centric approach, we can harness the power of microbes to usher in a new era of personalized and precision medicine, where microbial-based interventions play a central role in promoting health and well-being.[35]

VI. ACKNOWLEDGMENT

I express my sincere appreciation to Professor A.D. Pawar, the Head of the Department of Microbiology at K.J. Somaiya College of Arts and Commerce Sciences in Kopargaon, Maharashtra, India, for their invaluable mentorship and steadfast encouragement during this research endeavor. I am profoundly grateful for their significant contributions to the progression of understanding within the realm of microbiology.

VII. CONFLICT OF INTREST

The author declares no conflict of interest**.**

REFERENCE

[1] Sawant, S. S., Patil, S. M., Gupta, V., & Kunda, N. K. (2020). Microbes as medicines: harnessing the power of bacteria in advancing cancer treatment. *International journal of molecular sciences*, *21*(20), 7575..

[2] Hui, M. L. Y., Tan, L. T. H., Letchumanan, V., He, Y. W., Fang, C. M., Chan, K. G., ... & Lee, L. H. (2021). The extremophilic actinobacteria: From microbes to medicine. *Antibiotics*, *10*(6), 682.

[3] Costantini, C., Renga, G., Sellitto, F., Borghi, M., Stincardini, C., Pariano, M., ... & Bellet, M. M. (2020). Microbes in the era of circadian medicine. *Frontiers in cellular and infection microbiology*, *10*, 30.

[4] Autenrieth, I. B. (2017). The microbiome in health and disease: a new role of microbes in molecular medicine. *Journal of Molecular Medicine*, *95*(1), 1-3.

[5] Goel, A. (2014). Microbes in agriculture and medicine. *Bio evolution*, *1*, 5-8.-135.

[6] Burragoni, S. G., & Jeon, J. (2021). Applications of endophytic microbes in agriculture, biotechnology, medicine, and beyond. *Microbiological Research*, *245*, 126691.

[7] Pawar, A., Jadhav, A., & Jadhav, P. (2022). A review on CRISPR/Cas 9 and its future prospective in Cancer Treatment. Scientist, 1(3), 3490-3497.

[8] Singh, V., Gohil, N., Ramirez Garcia, R., Braddick, D., & Fofié, C. K. (2018). Recent advances in CRISPR-Cas9 genome editing technology for biological and biomedical investigations. *Journal of cellular biochemistry*, *119*(1), 81-94.

[9] Charpentier, E. (2015). CRISPR-Cas9: how research on a bacterial RNA-guided mechanism opened new perspectives in biotechnology and

biomedicine. *EMBO molecular medicine*, *7*(4), 363-365.

[10] Getahun, Y. A., Ali, D. A., Taye, B. W., & Alemayehu, Y. A. (2022). Multidrug-Resistant Microbial Therapy Using Antimicrobial Peptides and the CRISPR/Cas9 System. *Veterinary Medicine: Research and Reports*, 173-190..

[11] Forbes, N. S., Coffin, R. S., Deng, L., Evgin, L., Fiering, S., Giacalone, M., ... & McFadden, G. (2018). White paper on microbial anti-cancer therapy and prevention. *Journal for immunotherapy of cancer*, *6*(1), 1-24.

[12] Snyder, A., Pamer, E., & Wolchok, J. (2015). Could microbial therapy boost cancer immunotherapy?. *Science*, *350*(6264), 1031-1032.

[13] Oka, A., & Sartor, R. B. (2020). Microbial-based and microbial-targeted therapies for inflammatory bowel diseases. *Digestive diseases and sciences*, *65*(3), 757-788.

[14] Gordillo Altamirano, F. L., & Barr, J. J. (2019). Phage therapy in the postantibiotic era. *Clinical microbiology reviews*, *32*(2), 10-1128.

[15] Chan, B. K., Abedon, S. T., & Loc-Carrillo, C. (2013). Phage cocktails and the future of phage therapy. *Future microbiology*, *8*(6), 769-783.

[16] Loc-Carrillo, C., & Abedon, S. T. (2011). Pros and cons of phage therapy. *Bacteriophage*, *1*(2), 111-114.

[17] Gopalakrishnan, V., Weiner, B., Ford, C. B., Sellman, B. R., Hammond, S. A., Freeman, D. J., ... & Henn, M. R. (2020). Intervention strategies for microbial therapeutics in cancer immunotherapy. *Immuno-Oncology Technology*, *6*, 9-17.

[18] Gharaibeh, R. Z., & Jobin, C. (2018). Microbiota and cancer immunotherapy: in search of microbial signals. *Gut*, gutjnl-2018.

[19] Huang, J., Duan, F., Xie, C., Xu, J., Zhang, Y., Wang, Y., ... & Leung, E. L. H. (2023). Microbes mediated immunogenic cell death in cancer immunotherapy. *Immunological Reviews*.

[20] Simpson, R. C., Shanahan, E. R., Batten, M., Reijers, I. L., Read, M., Silva, I. P., ... & Long, G. V. (2022). Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. *Nature medicine*, *28*(11), 2344-2352.

[21] Riglar, D. T., & Silver, P. A. (2018). Engineering bacteria for diagnostic and therapeutic applications. *Nature Reviews Microbiology*, *16*(4), 214-225.

[22] Pedrolli, D. B., Ribeiro, N. V., Squizato, P. N., de Jesus, V. N., Cozetto, D. A., Tuma, R. B., ... & Cerri, M. O. (2019). Engineering microbial living therapeutics: the synthetic biology toolbox. *Trends in biotechnology*, *37*(1), 100-115.

[23] Charbonneau, M. R., Isabella, V. M., Li, N., & Kurtz, C. B. (2020). Developing a new class of engineered live bacterial therapeutics to treat human diseases. *Nature Communications*, *11*(1), 1738.

[24] Shen, H., Aggarwal, N., Wun, K. S., Lee, Y. S., Hwang, I. Y., & Chang, M. W. (2022). Engineered microbial systems for advanced drug delivery. *Advanced Drug Delivery Reviews*, *187*, 114364.

[25] Pandya, J., Adiga, R. S., Akash, K., Chadhmika, C. H., Niveditha, K., & Kar, D. (2023). Bioengineering Microbes for Improved Nutritional Value and Health Benefits.

[26] Jadhav, A., & Pawar, A. (2023). A Review on Unveiling the Secrets of Epitranscriptomics: RNA Modifications in Health and Diseases. *Micro Environer*, *3*(02). Retrieved from https://microenvironer.com/micro/article/view/33

[27] Woodworth, M. H., Sitchenko, K. L., Carpentieri, C., Friedman-Moraco, R. J., Wang, T., & Kraft, C. S. (2017). Ethical considerations in microbial therapeutic clinical trials. *The New Bioethics*, *23*(3), 210-218.

[28] Kalın, G., Alp, E., Chouaikhi, A., & Roger, C. (2023). Antimicrobial Multidrug Resistance: Clinical Implications for Infection Management in Critically Ill Patients. *Microorganisms*, *11*(10), 2575.

[29] Guaní-Guerra, E., Santos-Mendoza, T., Lugo-Reyes, S. O., & Terán, L. M. (2010). Antimicrobial peptides: general overview and clinical implications in human health and disease. *Clinical immunology*, *135*(1), 1-11.

[30] Chieng, C. C., Kong, Q., Liou, N. S., Khasriya, R., & Horsley, H. (2023). The clinical implications of bacterial pathogenesis and mucosal immunity in chronic urinary tract infection. *Mucosal Immunology*.

[31] Oka, A., & Sartor, R. B. (2020). Microbial-based and microbial-targeted therapies for inflammatory

bowel diseases. *Digestive diseases and sciences*, *65*(3), 757-788.

[32] Petrof, E. O., Claud, E. C., Gloor, G. B., & Allen-Vercoe, E. (2013). Microbial ecosystems therapeutics: a new paradigm in medicine?. *Beneficial microbes*, *4*(1), 53-65.

[33] Sharifi, S., Fathi, N., Memar, M. Y., Hosseiniyan Khatibi, S. M., Khalilov, R., Negahdari, R., .& Maleki Dizaj, S. (2020). Anti-microbial activity of curcumin nanoformulations: New trends and future perspectives. *Phytotherapy Research*,*34*(8), 1926-1946.

[34] Nagarethinam, S., Naik, A. N., Udupa, N., Rao, V. J., & Vanathi, M. B. (2012). Microbial L-Asparaginase and its future prospects. *Asian Journal of Medical Research*, *1*(4), 159-160.

[35] Grady, N. G., Petrof, E. O., & Claud, E. C. (2016, December). Microbial therapeutic interventions. In *Seminars in Fetal and Neonatal Medicine* (Vol. 21, No. 6, pp. 418-423). WB Saunders.